Factor H autoantibodies in patients with antiphospholipid syndrome and thrombosis

Journal of Rheumatology

Volumn 42, Issue 10, 2015, Pages 1786-1793

  Zadura, Anna Foltyn ^a   Memon, Ashfaque A ^b   Stojanovich, Ljudmila ^c   Perricone, Carlo ^d   Conti, Fabrizio ^d   Valesini, Guido ^d   Bogdanovic, Gordana ^c   Hillarp, Andreas ^e   Shoenfeld, Yehuda ^f   Sundquist, Jan ^b   Leffler, Jonatan ^g   Svensson, Peter J ^a   Trouw, Leendert A ^h   Blom, Anna M ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c University Medical Center   (Sweden)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Department of Clinical Chemistry and Transfusion Medicine Halland Hospital   (United Kingdom)

^f Sheba Medical Center   (United Kingdom)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Deep venous thrombosis; FH autoantibodies; Systemic lupus erythematosus; Thrombosis

Indexed keywords

AUTOANTIBODY; COMPLEMENT FACTOR H; BIOLOGICAL MARKER;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY ANTIPHOSPHOLIPID SYNDROME; SERBIA; SWEDEN; THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VERY ELDERLY; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; DISEASE COURSE; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; COMPLEMENT FACTOR H; DISEASE PROGRESSION; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; REFERENCE VALUES; RISK ASSESSMENT; SERBIA; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SWEDEN; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84943302788     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150185     Document Type: Article

References (37)

1. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785-97.
2. Trouw LA, Blom AM, Gasque P. Role of complement and complement regulators in the removal of apoptotic cells. Mol Immunol 2008;45:1199-207.
3. Ballanti E, Perricone C, Greco E, Ballanti M, Di Muzio G, Chimenti MS, et al. Complement and autoimmunity. Immunol Res 2013;56:477-91.
4. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-63.
5. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008;111:1512-4.
6. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010;115:379-87.
7. Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2010;25:136-44.
8. Foltyn Zadura A, Zipfel PF, Bokarewa MI, Sturfelt G, Jonsen A, Nilsson SC, et al. Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res Ther 2012;14:R185.
9. Zipfel PF, Edey M, Heinen S, Jozsi M, Richter H, Misselwitz J, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007;3:e41.
10. Skerka C, Zipfel PF, Muller D, Micklisch S, Riedl M, Zimmerhackl LB, et al. The autoimmune disease DEAP-hemolytic uremic syndrome. Semin Thromb Hemost 2010;36:625-32.
11. Reynaud Q, Lega JC, Mismetti P, Chapelle C, Wahl D, Cathébras P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2014;13:595-608.
12. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
13. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4.
14. Guerin J, Feighery C, Sim RB, Jackson J. Antibodies to beta2-glycoprotein I-a specific marker for the antiphospholipid syndrome. Clin Exp Immunol 1997;109:304-9.
15. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol 2007;28:184-92.
16. Oku K, Amengual O, Atsumi T. Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. Eur J Clin Invest 2012;42:1126-35.
17. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005;52:2120-4.
18. Stojanovich L, Markovic O, Marisavljevic D, Elezovic I, Ilijevski N, Stanisavljevic N. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study. Lupus 2012;21:338-45.
19. Djokovic A, Stojanovich L, Kontic M, Stanisavljevic N, Radovanovic S, Marisavljevic D. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. Isr Med Assoc J 2014;16:162-7.
20. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
21. Isma N, Svensson PJ, Gottsater A, Lindblad B. Prospective analysis of risk factors and distribution of venous thromboembolism in the population-based Malmö Thrombophilia Study (MATS). Thromb Res 2009;124:663-6.
22. Blom AM, Kask L, Dahlbäck B. CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b. Mol Immunol 2003;39:547-56.
23. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis Rheum 2002;46:1019-27.
24. Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C, et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009;46:447-50.
25. Trouw LA, Roos A, Daha MR. Autoantibodies to complement components. Mol Immunol 2001;38:199-206.
26. Trouw LA, Bengtsson AA, Gelderman KA, Dahlbäck B, Sturfelt G, Blom AM. C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem 2007;282:28540-8.
27. Leffler J, Herbert AP, Norström E, Schmidt CQ, Barlow PN, Blom AM, et al. Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. J Biol Chem 2010;285:3766-76.
28. Romay-Penabad Z, Liu XX, Montiel-Manzano G, Papalardo De Martinez E, Pierangeli SS. C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann N Y Acad Sci 2007;1108:554-66.
29. Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009;68:1030-5.
30. Breen KA, Seed P, Parmar K, Moore GW, Stuart-Smith SE, Hunt BJ. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost 2012;107:423-9.
31. Ferluga J, Yu BB, Guerin J, Jackson J, Sim RB. Similarities between complement factor H and β2 glycoprotein 1: phospholipid binding and autoantibodies. Mol Immunol 1998;35:375.
32. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012;12:313-7.
33. Ferluga J, Kishore U, Sim RB. A potential anti-coagulant role of complement factor H. Mol Immunol 2014;59:188-93.
34. Rayes J, Roumenina LT, Dimitrov JD, Repesse Y, Ing M, Christophe O, et al. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 2014;123:121-5.
35. Brooimans RA, van der Ark AA, Buurman WA, van Es LA, Daha MR. Differential regulation of complement factor H and C3 production in human umbilical vein endothelial cells by IFN-gamma and IL-1. J Immunol 1990;144:3835-40.
36. Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, et al. Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood 2009;114:4538-45.
37. Cervera R, Boffa MC, Khamashta MA, Hughes GR. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009;18:889-93.